You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site


Go back

Product overview

Duodart is a treatment for patients with moderate-to-severe symptoms of benign prostate enlargement (BPE).1

Duodart reduces the risk of acute urinary retention (AUR) and the need for BPH-related surgery by reducing prostate size, improving urinary flow and alleviating symptoms.


Support materials

Duodart prescribing information for your support


  1. Duodart Datasheet GDS15/IPI 12 issued on 11th April 2016
  2. Roehrborn CG, Oyarzabal Perez I, Roos EP, Calomfirescu N, Brotherton B, Wang F, et al. Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results. BJU Int 2015; 116(3): 450–459.
  3. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57(1): 123–131.

Adverse Events must be reported. For products related to GSK Pakistan, please report adverse events via email at or call us at +92 (21) 111 475 725 - Ext: 7&8.

Duodart is a trademark of GlaxoSmithKline group of companies. GlaxoSmithKline Pakistan Limited is a member of GlaxoSmithKline group of companies. (c) GlaxoSmithKline Pakistan Limited